--- title: "Kazia Therapeutics (KZIA) news: offering" url: "https://aibio.space/companies/kazia-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KZIA offering news: Kazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report." --- KZIA Kazia Therapeutics Limited NASDAQ · Australia # Kazia Therapeutics (KZIA) news KZIA offering news Listings · 2026-03-30 ## [Kazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report](https://aibio.space/news/kazia-reports-aud-69-46-million-cash-after-us-46-51-million-pipe-half/) Ordinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b). ## Latest Kazia Therapeutics news 1. 2025-12-02 Financings [Kazia Therapeutics prices $50.0 million private placement at $5.00 per ADS](https://aibio.space/news/kazia-therapeutics-prices-50-0-million-private-placement-5-00-ads/) The deal has no common warrant coverage but includes prefunded warrants. Kazia expects net proceeds of approximately $46.5 million and says its cash runway would extend into the second half of 2028. 2. 2025-10-31 Distress [Kazia Therapeutics says 20-F is late as audit procedures are not complete](https://aibio.space/news/kazia-therapeutics-says-20-f-late-audit-procedures-not-complete/) The company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date. ## Kazia Therapeutics at a glance - **Ticker**: KZIA - **Listing**: NASDAQ - **Country**: Australia - **Cash, Dec 31, 2025**: A$69.5 million ### Related companies - [Identifai Genetics](https://aibio.space/companies/identifai-genetics/) ASX: ID1 - [Biotron](https://aibio.space/companies/biotron/) ASX: BIT - [Terragen Holdings](https://aibio.space/companies/terragen/) ASX: TGH - [Argenica Therapeutics](https://aibio.space/companies/argenica-therapeutics/) ASX: AGN - [Immutep](https://aibio.space/companies/immutep/) ASX: IMM - [Prescient Therapeutics](https://aibio.space/companies/prescient-therapeutics/) ASX: PTX - [Neuroscientific Biopharmaceuticals](https://aibio.space/companies/neuroscientific-biopharmaceuticals/) ASX: NSB - [Incannex Healthcare](https://aibio.space/companies/incannex-healthcare/) NASDAQ: IXHL ### Also on NASDAQ - [Novavax](https://aibio.space/companies/novavax/) NVAX - [SELLAS Life Sciences Group](https://aibio.space/companies/sellas-life-sciences/) SLS - [Atea Pharmaceuticals](https://aibio.space/companies/atea-pharmaceuticals/) AVIR - [Humacyte](https://aibio.space/companies/humacyte/) HUMA - [TuHURA Biosciences](https://aibio.space/companies/tuhura-biosciences/) HURA - [Baird Medical Investment Holdings](https://aibio.space/companies/baird-medical-investment/) BDMD ## What Kazia Therapeutics does Kazia Therapeutics Limited is an emerging oncology-focused biotechnology company with a portfolio of development candidates across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Its lead program is paxalisib, formerly known as GDC-0084, an investigational brain-penetrant inhibitor of the PI3K, Akt and mTOR pathway that was designed to treat brain cancer. Genentech developed paxalisib, and Kazia entered a worldwide exclusive license for the asset in October 2016. The company says paxalisib is the only PI3K inhibitor in mainstream clinical development known to cross the blood-brain barrier. Its clinical strategy rests on three pillars: adult brain cancer, pediatric brain cancer and brain metastases. In the adult glioblastoma program, paxalisib was tested in GBM AGILE, a phase II/III adaptive platform study sponsored by the Global Coalition for Adaptive Research. The paxalisib arm did not graduate to the second stage, and approximately 150 patients were enrolled in the first stage. The filing says paxalisib has orphan drug designation for glioblastoma and glioma and Fast Track designation for glioblastoma. | Product or program | What it is | Stage | |---|---|---| | Paxalisib (GDC-0084) | Brain-penetrant PI3K, Akt and mTOR pathway inhibitor designed to treat brain cancer | investigational | Summarised from the company's [20-F filed Nov 7, 2025](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/d908386d20f.htm). ## Kazia Therapeutics annual financials | Line | FY ended Jun 30, 2025 | FY ended Jun 30, 2024 | |---|---|---| | Revenue | [A$42,000](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | [A$2.3 million](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | | Research and development | [A$7.3 million](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | [A$17.4 million](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | | Net income (loss) | [-A$20.7 million](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | [-A$26.8 million](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | | Cash from operations | [-A$13.3 million](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | [-A$9.6 million](https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/) | | Cash and equivalents | [A$4.3 million](https://www.sec.gov/Archives/edgar/data/1075880/000121390026035886/) | [A$1.7 million](https://www.sec.gov/Archives/edgar/data/1075880/000121390026035886/) | Latest balance sheet, Dec 31, 2025 (6-K): cash and equivalents A$69.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Kazia Therapeutics Has Kazia Therapeutics raised money recently? Our latest story on this, dated Mar 30, 2026: "Kazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kazia-reports-aud-69-46-million-cash-after-us-46-51-million-pipe-half/). What is the ticker symbol of Kazia Therapeutics? Kazia Therapeutics Limited trades under the ticker KZIA on NASDAQ. Where is Kazia Therapeutics listed? Kazia Therapeutics Limited is listed on NASDAQ. What is the SEC CIK of Kazia Therapeutics? The SEC Central Index Key (CIK) for Kazia Therapeutics Limited is 1075880. Its filings are on SEC EDGAR. How many shares does Kazia Therapeutics have outstanding? 809,418,734 shares as of 2025-06-30, per the cover page of its 20-F filed 2025-11-07. Which country or territory is Kazia Therapeutics listed under? Our directory records Kazia Therapeutics Limited under Australia. What does Kazia Therapeutics do? Our directory classifies Kazia Therapeutics Limited as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Kazia Therapeutics? The ISIN recorded for Kazia Therapeutics Limited is US48669G3039. Does aibio.space cover Kazia Therapeutics? aibio.space lists Kazia Therapeutics Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Kazia Therapeutics incorporated? SEC records list its state or country of incorporation as C3. What does Kazia Therapeutics develop? Kazia Therapeutics Limited is an emerging oncology-focused biotechnology company with a portfolio of development candidates across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Its lead program is paxalisib, formerly known as GDC-0084, an investigational brain-penetrant inhibitor of the PI3K, Akt and mTOR pathway that was designed to treat brain cancer. What is Paxalisib (GDC-0084) from Kazia Therapeutics? Paxalisib (GDC-0084): Brain-penetrant PI3K, Akt and mTOR pathway inhibitor designed to treat brain cancer Stage: investigational. What is the latest Kazia Therapeutics (KZIA) stock news? Our latest story on Kazia Therapeutics, dated Mar 30, 2026: "Kazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report". Ordinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b). [Source](https://aibio.space/news/kazia-reports-aud-69-46-million-cash-after-us-46-51-million-pipe-half/). How long will Kazia Therapeutics's cash last? From our story of Mar 30, 2026: The report's dollar figures are Australian dollars: the going concern note gives the cash balance of $69,459,980 at 31 December 2025 as AUD 69.46 million. [Source](https://aibio.space/news/kazia-reports-aud-69-46-million-cash-after-us-46-51-million-pipe-half/). Is Kazia Therapeutics in financial distress? Our latest distress story, dated Oct 31, 2025: "Kazia Therapeutics says 20-F is late as audit procedures are not complete". The company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date. [Source](https://aibio.space/news/kazia-therapeutics-says-20-f-late-audit-procedures-not-complete/). ## Investor discussion: Kazia Therapeutics Members talk about Kazia Therapeutics (KZIA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Kazia Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000121390026035886/ea028366101ex99-1.htm) 2. 2026-03-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312526116176/d45630dex991.htm) 3. 2025-12-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525326779/d328722d6k.htm) 4. 2025-12-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525309627/d81135d6k.htm) 5. 2025-12-02 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525305250/d15328dex991.htm) 6. 2025-11-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525286169/d24645d6k.htm) 7. 2025-10-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525260712/d42131dnt20f.htm) 8. 2025-07-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525157083/d83871dex991.htm) 9. 2025-06-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525139172/d116207dex991.htm) 10. 2025-06-10 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525138448/d926165dex991.htm) 11. 2025-06-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525135383/d832779dex991.htm) 12. 2025-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525120331/d904836dex991.htm) 13. 2025-04-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525080819/d940742d6k.htm) 14. 2025-03-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525053468/d121422dex991.htm) 15. 2025-02-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525018913/d841350dex991.htm) 16. 2025-01-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312525004117/d923802d424b5.htm) 17. 2024-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312524255197/d853396d6k.htm) 18. 2024-11-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1075880/000119312524249817/d872361dnt20f.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KZIA on TradingView](https://www.tradingview.com/symbols/NASDAQ-KZIA/). ## SEC filings and registration - **SEC name**: Kazia Therapeutics Ltd - **CIK**: 1075880 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: KZIA (Nasdaq) - **State or country of incorporation**: C3 - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer - **Business address**: THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, 2000 - **Phone**: 01161298780088 - **Shares outstanding**: 809,418,734 as of 2025-06-30 (20-F filed 2025-11-07) - **Former names**: NOVOGEN LTD ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1075880/000121390026101967/ea0305873-6k_kazia.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1075880/000121390026101400/ea030595301-6k_kazia.htm) filed 2026-09-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1075880/000121390026096263/ea0304307-6k_kazia.htm) filed 2026-09-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1075880/000121390026095348/ea0303976-6k_kazia.htm) filed 2026-08-31 - [6-K](https://www.sec.gov/Archives/edgar/data/1075880/000121390026095310/ea0303820-6k_kazia.htm) filed 2026-08-31 - [424B5](https://www.sec.gov/Archives/edgar/data/1075880/000121390026095303/ea0303882-424b5_kazia.htm) filed 2026-08-31 - [6-K](https://www.sec.gov/Archives/edgar/data/1075880/000121390026094603/ea0303789-6k_kazia.htm) filed 2026-08-28 - [424B5](https://www.sec.gov/Archives/edgar/data/1075880/000121390026094600/ea0303789-424b5_kazia.htm) filed 2026-08-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001075880), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Kazia Therapeutics Limited is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KZIA, recorded under Australia. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Kazia Therapeutics Limited - **Ticker**: KZIA - **Listing**: NASDAQ - **Country or territory**: Australia - **Business scope**: Biotechnology - **ISIN**: US48669G3039 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KZIA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/kazia-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kazia Therapeutics (KZIA) news: offering", 2026-10-31, https://aibio.space/companies/kazia-therapeutics/